Gene Therapy for Rare Cause of Blindness Gets FDA Designation – Rare Disease Report
|
Gene Therapy for Rare Cause of Blindness Gets FDA Designation
Rare Disease Report The U.S. Food and Drug Administration (FDA) has granted orphan drug designation towards gene therapy to treat X-linked retinitis pigmentosa (XLRP). The therapy is being developed by Applied Genetic Technologies Corporation in collaboration with … |
